MYCN and neoplasm: For example, in MDM2 haploinsufficient MYCN transgenic mice, tumor onset is delayed and survival is prolonged, and in human xenograft models, MDM2 knockdown significantly inhibits tumor growth through a p53-dependent mechanism (Chen et al., 2009).